NCT04144140View on ClinicalTrials.gov

Study of Intratumorally Administered Stimulator of Interferon Genes (STING) Agonist E7766 in Participants With Advanced Solid Tumors or Lymphomas - INSTAL-101

PHASE1TerminatedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

February 24, 2020

Primary Completion Date

July 26, 2022

Study Completion Date

July 26, 2022

Conditions
LymphomaAdvanced Solid Tumors
Interventions
DRUG

E7766

E7766, solution, intratumorally

Trial Locations (13)

15232

University of Pittsburgh Medical Center and Hillman Cancer Center, Pittsburgh

28041

Hospital Universitario 12 de Octubre, Madrid

28050

START Madrid, Madrid

33136

University of Miami Hospital Sylvester Comprehensive Cancer Center, Miami

46010

INCLIVA Hospital Clínico Universitario de Valencia, Valencia

94805

Institut Gustave Roussy, Villejuif

06510

Yale New Haven Hospital, New Haven

02114

Massachusetts General Hospital Cancer Center, Boston

02215

Beth Israel Deaconess Medical Center, Boston

Dana-Farber Cancer Institute, Boston

06351

Samsung Medical Center, Seoul

08035

Hospital Universitario Vall d'Hebrón, Barcelona

W12 0HS

Imperial College Healthcare NHS Trust, London

Sponsors

Collaborators (1)

H3 Biomedicine Inc.
All Listed Sponsors
collaborator

H3 Biomedicine Inc.

INDUSTRY

lead

Eisai Inc.

INDUSTRY